Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer | OncLive

Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian Cancer

March 4, 2020

Lori Brisbin, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

Lori Brisbin, vice president of precision medicine at Texas Oncology, discusses using Trapelo, an automated tool to track precision medicine guidelines in various cancers, in patients with ovarian cancer.

In 2019, Trapelo was in a beta trial with 50 different physicians, ranging from those who practice precision medicine frequently to those who are less familiar, explains Brisbin. Ovarian cancer testing standards were added to this tool with the emergence of PARP inhibitors, which made it necessary to perform molecular tests on patients with ovarian cancer to find those with BRCA1/2 mutations, says Brisbin.

Guidelines for performing genetic testing on patients with ovarian cancer are complicated, which is why Trapelo may be useful to physicians in their daily practice, according to Brisbin. Trapelo will help answer questions such as, “Should we do germline or somatic testing?” and “What phase of the disease and in what setting of disease management should we test?” The ovarian cancer guidelines are different than the breast cancer guidelines, which Trapelo will help track, concludes Brisbin.


x